Researchers Deform Cells to Deliver RNA, Proteins, and Nanoparticles for Many Applications
|
By LabMedica International staff writers Posted on 06 Feb 2013 |

Image: As cells squeeze through a narrow channel, tiny holes open in their membranes, allowing large molecules such as RNA to pass through (Photo courtesy of Armon Sharei and Emily Jackson).
Researchers have found a safe and effective way to push large molecules through the cell membrane by jamming the cells through a narrow constriction that opens up very small, temporary holes in the membrane. Any large molecules drifting outside the cell—such as proteins, RNA, or nanoparticles—can slide through the membrane during this disruption.
Living cells are enclosed by a membrane that closely controls what gets in and out of the cell. This barrier is necessary for cells to control their internal environment, but it makes it more difficult for scientists to deliver large molecules such as nanoparticles for imaging, or proteins that can reprogram them into pluripotent stem cells.
Using this technique, the Massachusetts Institute of Technology (MIT; Cambridge, MA, USA: www.mit.edu) researchers were able to deliver reprogramming proteins and create induced pluripotent stem cells with a success rate 10 to 100 times superior than any existing application. They also used it to deliver nanoparticles, including quantum dots and carbon nanotubes, which can be used to image cells and track what is occurring inside them.
“It’s very useful to be able to get large molecules into cells. We thought it might be interesting if you could have a relatively simple system that could deliver many different compounds,” said Dr. Klavs Jensen, a professor of chemical engineering, professor of materials science and engineering, and a senior author of a paper describing the new device in this week’s issue of the Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Scientists had earlier developed several approaches to get large molecules into cells, but all of them have downsides. DNA or RNA can be parceled into viruses, which are proficient at entering cells, but that approach carries the risk that some of the viral DNA will be incorporated into the host cell. This application is commonly used in lab experiments but has not been approved by the US Food and Drug and Administration (FDA) for use in human patients.
Another way to transport large molecules into a cell is to tag them with a short protein that can penetrate the cell membrane and tug the larger payload along with it. Alternatively, DNA or proteins can be packaged into synthetic nanoparticles that can enter cells. However, these systems frequently need to be remodified depending on the type of cell and substance being delivered. Moreover, with some nanoparticles, a lot of the material ends up stuck in protective sacs called endosomes inside the cell, and there can be potential toxic side effects.
Electroporation, which involves jolting cells with electricity that opens up the cell membrane, is a more general approach but can be damaging to both cells and the material being delivered.
The new MIT system appears to work for many cell types—up to now, the researchers have successfully tested it with more than a dozen types, including both human and mouse cells. It also works in cells taken directly from human patients, which are typically much more difficult to engineer than human cell lines grown specifically for lab research.
The new device builds on earlier research by Jensen and Langer’s labs, in which they used microinjection to push large molecules into cells as they flowed through a microfluidic device. This was not as fast as the researchers hoped, but during these studies, they discovered that when a cell is squeezed through a narrow tube, small holes open in the cell membrane, allowing neighboring molecules to diffuse into the cell.
To take advantage of that, the researchers built rectangular microfluidic chips, about the size of a quarter, with 40 to 70 parallel channels. Cells are suspended in a solution with the material to be delivered and flowed through the channel at high speed—approximately one meter per second. Halfway through the channel, the cells pass through a constriction about 30%–80% smaller than the cells’ diameter. The cells do not sustain any permanent damage, and they maintain their normal functions after the treatment.
The scientists are now studying stem cell manipulation, which has potential for treating a wide range of diseases. They have already shown that they can convert human fibroblast cells into pluripotent stem cells, and now plan to start working on delivering the proteins needed to differentiate stem cells into specialized tissues.
Another promising application is delivering quantum dots—nanoparticles made of semiconducting metals that fluoresce. These dots hold promise for labeling individual proteins or other molecules inside cells, but scientists have had trouble getting them through the cell membrane without being trapped in endosomes.
In earlier work in November 2012, working with MIT graduate student Jungmin Lee and chemistry professor Dr. Moungi Bawendi, the researchers demonstrated that they could get quantum dots inside human cells grown in the laboratory, without the particles becoming confined in endosomes or clumping together. They are now working on getting the dots to tag specific proteins inside the cells.
The researchers are also exploring the possibility of using the new system for vaccination. In theory, scientists could take immune cells from a patient, run them through the microfluidic device and expose them to a viral protein, and then put them back in the patient. Once inside, the cells could provoke an immune response that would confer immunity against the target viral protein.
Related Links:
Massachusetts Institute of Technology
Living cells are enclosed by a membrane that closely controls what gets in and out of the cell. This barrier is necessary for cells to control their internal environment, but it makes it more difficult for scientists to deliver large molecules such as nanoparticles for imaging, or proteins that can reprogram them into pluripotent stem cells.
Using this technique, the Massachusetts Institute of Technology (MIT; Cambridge, MA, USA: www.mit.edu) researchers were able to deliver reprogramming proteins and create induced pluripotent stem cells with a success rate 10 to 100 times superior than any existing application. They also used it to deliver nanoparticles, including quantum dots and carbon nanotubes, which can be used to image cells and track what is occurring inside them.
“It’s very useful to be able to get large molecules into cells. We thought it might be interesting if you could have a relatively simple system that could deliver many different compounds,” said Dr. Klavs Jensen, a professor of chemical engineering, professor of materials science and engineering, and a senior author of a paper describing the new device in this week’s issue of the Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Scientists had earlier developed several approaches to get large molecules into cells, but all of them have downsides. DNA or RNA can be parceled into viruses, which are proficient at entering cells, but that approach carries the risk that some of the viral DNA will be incorporated into the host cell. This application is commonly used in lab experiments but has not been approved by the US Food and Drug and Administration (FDA) for use in human patients.
Another way to transport large molecules into a cell is to tag them with a short protein that can penetrate the cell membrane and tug the larger payload along with it. Alternatively, DNA or proteins can be packaged into synthetic nanoparticles that can enter cells. However, these systems frequently need to be remodified depending on the type of cell and substance being delivered. Moreover, with some nanoparticles, a lot of the material ends up stuck in protective sacs called endosomes inside the cell, and there can be potential toxic side effects.
Electroporation, which involves jolting cells with electricity that opens up the cell membrane, is a more general approach but can be damaging to both cells and the material being delivered.
The new MIT system appears to work for many cell types—up to now, the researchers have successfully tested it with more than a dozen types, including both human and mouse cells. It also works in cells taken directly from human patients, which are typically much more difficult to engineer than human cell lines grown specifically for lab research.
The new device builds on earlier research by Jensen and Langer’s labs, in which they used microinjection to push large molecules into cells as they flowed through a microfluidic device. This was not as fast as the researchers hoped, but during these studies, they discovered that when a cell is squeezed through a narrow tube, small holes open in the cell membrane, allowing neighboring molecules to diffuse into the cell.
To take advantage of that, the researchers built rectangular microfluidic chips, about the size of a quarter, with 40 to 70 parallel channels. Cells are suspended in a solution with the material to be delivered and flowed through the channel at high speed—approximately one meter per second. Halfway through the channel, the cells pass through a constriction about 30%–80% smaller than the cells’ diameter. The cells do not sustain any permanent damage, and they maintain their normal functions after the treatment.
The scientists are now studying stem cell manipulation, which has potential for treating a wide range of diseases. They have already shown that they can convert human fibroblast cells into pluripotent stem cells, and now plan to start working on delivering the proteins needed to differentiate stem cells into specialized tissues.
Another promising application is delivering quantum dots—nanoparticles made of semiconducting metals that fluoresce. These dots hold promise for labeling individual proteins or other molecules inside cells, but scientists have had trouble getting them through the cell membrane without being trapped in endosomes.
In earlier work in November 2012, working with MIT graduate student Jungmin Lee and chemistry professor Dr. Moungi Bawendi, the researchers demonstrated that they could get quantum dots inside human cells grown in the laboratory, without the particles becoming confined in endosomes or clumping together. They are now working on getting the dots to tag specific proteins inside the cells.
The researchers are also exploring the possibility of using the new system for vaccination. In theory, scientists could take immune cells from a patient, run them through the microfluidic device and expose them to a viral protein, and then put them back in the patient. Once inside, the cells could provoke an immune response that would confer immunity against the target viral protein.
Related Links:
Massachusetts Institute of Technology
Latest BioResearch News
- Disease Gene Discovery Advances Diagnosis of Rare Movement Disorders
- Genetic Discovery Could Improve Diagnosis of Drug-Resistant Epilepsy
- Genetic Discovery May Improve Diagnosis of Rare Dementia Subtype
- Mass Spectrometry Technique Detects Protein and Sugar Changes in Neurodegeneration
- Barcoded DNA Sheds Light on Hidden Complexities in Breast Cancer Detection
- CRISPR-Based Platform Pinpoints Drivers of Acute Myeloid Leukemia in Patient Cells
- Protective Brain Protein Emerges as Biomarker Target in Alzheimer’s Disease
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
Channels
Clinical Chemistry
view channel
New Plasma Tau Assay Improves Prediction of Alzheimer’s Progression
Predicting which patients with early symptomatic Alzheimer’s disease will decline more rapidly remains a key challenge in both research and patient care. Growing interest in tau biology, along with advances... Read more
Routine Blood Markers Predict Heart Failure Risk in Prediabetes
Heart failure prevention relies on finding high-risk adults before symptoms appear, yet effective stratification remains difficult in routine care. Prediabetes affects an estimated 115.2 million U.... Read moreMolecular Diagnostics
view channel
Blood Test Helps Guide Treatment in Older Women with Breast Cancer
Older women with estrogen receptor–positive breast cancer often face difficult decisions about treatment, especially when surgery and radiation can lead to side effects such as scarring, swelling, infection... Read more
Liquid Biopsy Method Pinpoints Disease Source From a Single Drop of Blood
Liquid biopsy offers a noninvasive way to assess disease, but many assays still lack reliable tissue-of-origin localization and robust performance for early cancer detection. Researchers now report a method... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read moreMicrobiology
view channel
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read more
New Chromogenic Culture Media Enable Rapid Detection of Candida Infections
Invasive Candida infections are challenging for healthcare systems, with some strains spreading rapidly in hospitals and showing resistance to multiple antifungal drugs. Candida auris is associated with... Read moreTechnology
view channel
New Electronic Pipette Enhances Workflows with Touchscreen Control
Manual pipetting remains a routine yet error-prone step that can affect reproducibility and throughput in clinical and research laboratories. Training demands and ergonomic strain also add variability... Read more
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
Automated MSI Test Gains IVDR Certification to Guide CRC Therapy
Treatment selection for metastatic colorectal cancer often requires knowledge of a tumor’s microsatellite instability (MSI) status. Timely results can help clinicians decide on immunotherapy options.... Read more








